ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
05 Nov 2018 22:59

EM Strategy: Brazil Breaking Out, EM Energy Remains Attractive

While the MSCI EM index remains in a well-defined downtrend, and we continue to recommend selectivity, we highlight several investable themes and...

Logo
622 Views
Share
10 Oct 2018 15:26

Para IV Winners and Losers - September 2018

This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...

Logo
546 Views
Share
20 Sep 2018 21:49

Global Equity Strategy: Opportunities in Japan and India

Our outlook for ex-U.S. markets (MSCI ACWI ex-U.S. index, local currency) remains neutral - bordering on cautious. Our concern stems from the...

Logo
593 Views
Share
bullishZensho Holdings
19 Sep 2018 14:40

BBSP ASIA Equity Asia Weekly Research - 19 Sep 2018

THE MAIN IDEA(Relative Value Approach in USD Terms)Long Term Allocation (Strategic view) Relative Value vs MXAP in USD terms⦁ NIKKEI/MXAP: Long...

Logo
440 Views
Share
10 Sep 2018 19:16

Para IV Winners and Losers - August 2018

This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...

Logo
367 Views
Share
x